ANGO

SEC source: 0001567619-22-001116 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,081

SEC source: 0001567619-22-001113 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 390,764

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.58 to $23.06, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-21-019404 · doc1.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · Sr. VP/GM, Global VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,291

F1 · shares: The exempt disposition of 953 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on October 31, 2019.

SEC source: 0001567619-21-018544 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,387

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.95 to $28.05, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-21-018407 · doc1.xml · derivative · entry 3

Centea Scott · CIK 0001823973 · Sr. VP/GM, Global VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires 2024-10-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options for one-fourth of the shares became exercisable on 10/24/2015, 10/24/2016, 10/24/2017 and 10/24/2018, respectively.

SEC source: 0001567619-21-018407 · doc1.xml · nonDerivative · entry 2

Centea Scott · CIK 0001823973 · Sr. VP/GM, Global VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,244

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $27.99, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-21-018407 · doc1.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · Sr. VP/GM, Global VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,244

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-017999 · doc1.xml · derivative · entry 3

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,748 shares

Expires 2023-07-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options for one-fourth of the shares became exercisable on 7/27/2017, 7/27/2018, 7/27/2019 and 7/27/2020, respectively.

SEC source: 0001567619-21-017999 · doc1.xml · nonDerivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,741

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.07 to $27.35, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-21-017999 · doc1.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,489

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-015951 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,139 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On October 16, 2019, the reporting person received a target grant of 50,139 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.exercise_date: On October 16, 2019, the reporting person received a target grant of 50,139 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.expiration_date: On October 16, 2019, the reporting person received a target grant of 50,139 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

SEC source: 0001567619-21-015951 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 369,533

F2 · shares: The exempt disposition of 9,021 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-015951 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,554

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 19,387 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-015952 · doc1.xml · derivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,945 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On October 16, 2019, the reporting person received a target grant of 6,945 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.exercise_date: On October 16, 2019, the reporting person received a target grant of 6,945 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.expiration_date: On October 16, 2019, the reporting person received a target grant of 6,945 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

SEC source: 0001567619-21-015952 · doc1.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,719

F2 · shares: The exempt disposition of 788 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-015952 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,507

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 2,685 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-015950 · doc1.xml · derivative · entry 3

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,195 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On October 16, 2019, the reporting person received a target grant of 6,195 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.exercise_date: On October 16, 2019, the reporting person received a target grant of 6,195 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.expiration_date: On October 16, 2019, the reporting person received a target grant of 6,195 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

SEC source: 0001567619-21-015950 · doc1.xml · nonDerivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,354

F2 · shares: The exempt disposition of 702 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-015950 · doc1.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,056

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 2,395 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-015946 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,357 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On October 16, 2019, the reporting person received a target grant of 8,357 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.exercise_date: On October 16, 2019, the reporting person received a target grant of 8,357 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.expiration_date: On October 16, 2019, the reporting person received a target grant of 8,357 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

SEC source: 0001567619-21-015946 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,308

F2 · shares: The exempt disposition of 1,231 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-015946 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,539

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 3,231 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-016023 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 34,938 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On July 18, 2018, the reporting person received a target grant of 34,938 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 40,528 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.exercise_date: On July 18, 2018, the reporting person received a target grant of 34,938 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 40,528 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.expiration_date: On July 18, 2018, the reporting person received a target grant of 34,938 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 40,528 shares of Common Stock were issued to the reporting person under this grant.

SEC source: 0001567619-21-016023 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,163

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F3 · shares: The exempt disposition of 21,532 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-016023 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 399,695

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F2 · shares: This acquisition of 40,528 shares of Common Stock of the Company represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-016025 · doc1.xml · derivative · entry 3

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,079 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On July 18, 2018, the reporting person received a target grant of 7,079 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 8,210 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.exercise_date: On July 18, 2018, the reporting person received a target grant of 7,079 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 8,210 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.expiration_date: On July 18, 2018, the reporting person received a target grant of 7,079 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 8,210 shares of Common Stock were issued to the reporting person under this grant.

SEC source: 0001567619-21-016025 · doc1.xml · nonDerivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,741

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F3 · shares: The exempt disposition of 3,130 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-016025 · doc1.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,871

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F2 · shares: This acquisition of 8,210 shares of Common Stock of the Company represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-016021 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,437 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On July 18, 2018, the reporting person received a target grant of 9,437 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 10,946 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.exercise_date: On July 18, 2018, the reporting person received a target grant of 9,437 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 10,946 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.expiration_date: On July 18, 2018, the reporting person received a target grant of 9,437 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 10,946 shares of Common Stock were issued to the reporting person under this grant.

SEC source: 0001567619-21-016021 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,081

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F3 · shares: The exempt disposition of 4,173 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-016021 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,254

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F2 · shares: This acquisition of 10,946 shares of Common Stock of the Company represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-016019 · doc1.xml · derivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,834 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On July 18, 2018, the reporting person received a target grant of 9,834 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 11,406 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.exercise_date: On July 18, 2018, the reporting person received a target grant of 9,834 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 11,406 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.expiration_date: On July 18, 2018, the reporting person received a target grant of 9,834 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 11,406 shares of Common Stock were issued to the reporting person under this grant.

SEC source: 0001567619-21-016019 · doc1.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,881

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F3 · shares: The exempt disposition of 3,347 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-016019 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,228

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F2 · shares: This acquisition of 11,406 shares of Common Stock of the Company represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-014233 · doc1.xml · derivative · entry 3

Meteny Dennis S · CIK 0001289336 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,726 shares

Expires 2021-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options for one-third of the shares were each exercisable beginning 8/12/2015, 8/12/2016 and 8/12/2017, respectively.

SEC source: 0001567619-21-014233 · doc1.xml · nonDerivative · entry 2

Meteny Dennis S · CIK 0001289336 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,694

SEC source: 0001567619-21-014233 · doc1.xml · nonDerivative · entry 1

Meteny Dennis S · CIK 0001289336 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,865

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-014231 · doc1.xml · derivative · entry 3

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,726 shares

Expires 2021-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options for one-third of the shares were each exercisable beginning 8/12/2015, 8/12/2016 and 8/12/2017, respectively.

SEC source: 0001567619-21-014231 · doc1.xml · nonDerivative · entry 2

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,204

SEC source: 0001567619-21-014231 · doc1.xml · nonDerivative · entry 1

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-014064 · doc1.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · Sr. VP/GM, Global VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,244

F1 · shares: The exempt disposition of 419 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-21-014055 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 359,167

F1 · shares: The exempt disposition of 2,105 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-21-014063 · doc1.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,661

F1 · shares: The exempt disposition of 318 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-21-014062 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,308

F1 · shares: The exempt disposition of 353 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-21-013935 · doc1.xml · nonDerivative · entry 1

REED JAN STERN · CIK 0001124181 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,717

F1 · shares: The acquisition of 5,738 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 5,738 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/21/2022.

SEC source: 0001567619-21-013923 · doc1.xml · derivative · entry 6

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,721

Underlying: Common Stock · 7,721 shares

Expires 2031-07-21

F6 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013923 · doc1.xml · derivative · entry 5

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,684

Underlying: Common Stock · 5,684 shares

Expires not disclosed

F5 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-013923 · doc1.xml · nonDerivative · entry 4

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,663

F4 · shares: The acquisition of 2,842 shares of Common Stock of the Company represents 2,842 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013917 · doc1.xml · derivative · entry 6

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,154

Underlying: Common Stock · 71,154 shares

Expires 2031-07-21

F6 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013917 · doc1.xml · derivative · entry 5

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,378

Underlying: Common Stock · 52,378 shares

Expires not disclosed

F5 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.